MedTrace Logo

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

NCT04908280 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

Conditions

  • Discoid Lupus Erythematosus

Interventions

DRUG

Ruxolitinib

1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.

Sponsors & Collaborators

Principal Investigators

  • Christopher T Richardson, MD, PhD · University of Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-04
Primary Completion
2024-03-04
Completion
2024-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04908280 on ClinicalTrials.gov